Hong Sun

机构：First Affiliated Hospital of Xi'an Jiaotong University · ORCID：0000-0002-6424-8713

发表论文 52 篇 · 总被引 1074 次 · h-index 18

代表论文

• The biomarkers related to immune related adverse events caused by immune checkpoint inhibitors (2020 · Journal of Experimental & Clinical Cancer Research · 被引 121)
• Co-delivery of doxorubicin and pH-sensitive curcumin prodrug by transferrin-targeted nanoparticles for breast cancer treatment (2017 · Oncology Reports · 被引 88)
• Pleiotrophin, a target of miR‐384, promotes proliferation, metastasis and lipogenesis in HBV‐related hepatocellular carcinoma (2017 · Journal of Cellular and Molecular Medicine · 被引 76)
• Pembrolizumab Plus Chemotherapy for Chinese Patients With Metastatic Squamous NSCLC in KEYNOTE-407 (2021 · JTO Clinical and Research Reports · 被引 52)
• A phase Ib/II study of cadonilimab (PD-1/CTLA-4 bispecific antibody) plus anlotinib as first-line treatment in patients with advanced non-small cell lung cancer (2023 · British Journal of Cancer · 被引 41)
• Immune checkpoint inhibitor‐related adverse events in lung cancer: Real‐world incidence and management practices of 1905 patients in China (2021 · Thoracic Cancer · 被引 40)